Study of Lung Proteins in Patients With Pneumonia

Sponsor
National Institutes of Health Clinical Center (CC) (NIH)
Overall Status
Recruiting
CT.gov ID
NCT00077909
Collaborator
(none)
750
1

Study Details

Study Description

Brief Summary

This study will examine the different types of proteins present in the lungs of patients with pneumonia to explore the causes of different types of the disease. Pneumonia is a condition that causes lung inflammation AND is often caused by an infection. It is usually diagnosed by lung x-rays and listening to the chest with a stethoscope. This method can diagnose pneumonia, but it does not provide information on the cause of the inflammation - information that might be helpful in guiding treatment. This study will measure proteins in the lungs of patients to see if certain proteins are associated with specific forms of pneumonia, and can thus serve as biomarkers for disease.

Patients undergoing diagnostic bronchoscopy at the NIH Clinical Center may participate in this study. Patients will undergo bronchoscopy and bronchoalveolar lavage as scheduled for their medical care. For this procedure, the patient's mouth and throat are numbed with lidocaine; a sedative may be given for comfort. A thin flexible tube called a bronchoscope is advanced through the nose or mouth into the lung airways to examine the airways carefully. Saline (salt water) is then injected through the bronchoscope into the air passage, acting as a rinse. A sample of fluid is then withdrawn for microscopic examination. Researchers in the current study will use some of the fluid obtained from the lavage to examine for protein content.

In addition to the bronchoscopy and bronchoalveolar lavage, participants will have about 2 tablespoons of blood drawn to compare blood test results with the results of the lung washings. Patients' medical records will be reviewed to obtain information on past medical history, current medical treatment, vital signs, and results of x-ray tests.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    OBJECTIVE:

    The objective of this study is to analyze bronchoalveolar lavage (BAL) fluid from patients with lung infiltrates in order to discover new biomarkers and protein/peptide expression patterns that are associated with specific types of pulmonary diseases and infections. Bronchoalveolar lavage (BAL) is a standard method to obtain lower airway samples to evaluate pulmonary infiltrates in order to diagnose infection, malignancy or non-infectious inflammation. After collecting the BAL (during a clinically indicated brochoscopy), samples are routinely sent to the clinical microbiology laboratory for stains, cultures and molecular analysis. We have recently developed a rapid, culture-independent method to identify unique peptide markers in BAL that identify specific bacterial species. We are expanding the scope of 04-CC-0119 that was based originally on collection of BAL supernatant only, to now collect, analyze and store whole (unprocessed) BAL. The availabilty of new methods of analyzing BAL will broaden the scope of the study to analyze BAL proteins, lung cells, and microbial pathogens. This will allow improved characterization of the host response to lung inflammation and infection and help to assess the feasibility of using the culture-independent approach on clinical BAL samples to identify specific pathogens.

    POPULATION:

    The study population will include all patients undergoing bronchoscopy for clinical indications at the Clinical Center who provide informed consent for chart review blood draw (optional), and analysis of BAL, as described in this protocol. We plan to acquire BAL samples that reflect a spectrum of community-acquired and opportunistic pathogens associated with pulmonary disease. In addition analysis of a range of non-infectious pulmonary processes (e.g. acute lung injury, acute respiratory distress syndrome and engraftment syndrome) is important to develop measures of sensitivity and specificity.

    DESIGN:

    This is a prospective observational study.

    OUTCOME:
    The expected outcome is to:

    Develop a database of protein mass profiles of BAL fluid linked to specific microbiologic diagnoses.

    To collect, analyze and store BAL to validate the usefulness of the genoproteomic culture-independent method of microbial identification.

    To analyze lung cells associated with infectious or inflammatory pulmonary condidtions.

    Our plan is to acquire 1,000 specimens from the Clinical Center with a range of clinical diagnoses including bacterial, viral, parasitic and fungal infections and sterile inflammation. When a sufficient number of samples in an individual category is collected (approximately 20-30), the samples will be analyzed with current proteomic techniques.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    750 participants
    Observational Model:
    Cohort
    Time Perspective:
    Cross-Sectional
    Official Title:
    Biomarkers and Protein Mass Expression Profiles in Bronchoalveolar Lavage From Patients With Lung Infiltrates
    Actual Study Start Date :
    Feb 20, 2004

    Arms and Interventions

    Arm Intervention/Treatment
    Group 1

    Patients with Infectious Pneumonia

    Group 2

    Patients with Non-Infectious Pneumonia

    Outcome Measures

    Primary Outcome Measures

    1. Peptide biomarker [Batch-driven analysis of samples.]

      Detection of peptide biomarker for infectious disease as a cause of pneumonia.

    2. Characterization of lung cells associated with pneumonia [Batch-driven analysis of samples.]

      Analyze lung cells associated with infectious or inflammatory pulmonary conditions.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    3 Years to 99 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    • INCLUSION CRITERIA:

    • All eligible patients undergoing diagnostic bronchoscopy who provide consent for proteomic analysis of BAL fluid supernatant and chart review of patient characteristics will be included in this study.

    • A parent/guardian may provide consent for a child age 17 or under and a Legally Authorized Representative (LAR) may provide consent for adults unable to consent.

    EXCLUSION CRITERIA:

    Patients undergoing bronchoscopy but not wanting to participate with either the chart review or the proteomic analysis of BAL fluid supernatant will be excluded.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland United States 20892

    Sponsors and Collaborators

    • National Institutes of Health Clinical Center (CC)

    Investigators

    • Principal Investigator: Anthony F Suffredini, M.D., National Institutes of Health Clinical Center (CC)

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    National Institutes of Health Clinical Center (CC)
    ClinicalTrials.gov Identifier:
    NCT00077909
    Other Study ID Numbers:
    • 040119
    • 04-CC-0119
    First Posted:
    Feb 13, 2004
    Last Update Posted:
    Aug 15, 2022
    Last Verified:
    Aug 11, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Keywords provided by National Institutes of Health Clinical Center (CC)
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 15, 2022